Alnylam Pharmaceuticals Inc (ALNY)vsRani Therapeutics Holdings Inc (RANI)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
RANI
Rani Therapeutics Holdings Inc
$1.14
+7.55%
HEALTHCARE · Cap: $139.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 309395% more annual revenue ($3.71B vs $1.20M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
RANI
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for RANI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -11.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : RANI
The strongest argument for RANI centers on Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while RANI is a value play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.41 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 17/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is an innovative biotechnology company focused on transforming the delivery of injectable therapeutics with its cutting-edge RaniPill™ technology, facilitating the oral administration of biologics. This proprietary platform is designed to enhance patient adherence and improve treatment outcomes, addressing key unmet needs in the healthcare sector. With a robust and diverse pipeline across various therapeutic areas, Rani Therapeutics is poised to disrupt traditional drug delivery systems while capitalizing on the growing demand for non-invasive alternatives. The company’s strategic partnerships and unwavering commitment to research and development underscore its potential for sustainable growth and significant impact within the pharmaceutical industry.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?